Cancer Research Institute, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China.
Dermatology Hospital, Southern Medical University, Guangzhou, China.
Cancer Med. 2019 Aug;8(9):4245-4253. doi: 10.1002/cam4.2332. Epub 2019 Jun 11.
The use of immunotherapy has achieved great advances in the treatment of cancer. Macrophages play a pivotal role in the immune defense system, serving both as phagocytes (removal of pathogens and cancer cells) and as antigen-presenting cells (activation of T cells). However, research regarding tumor immunotherapy is mainly focused on the adaptive immune system. The usefulness of innate immune cells (eg, macrophages) in the treatment of cancer has not been extensively investigated. Recent advances in synthetic biology and the increasing understanding of the cluster of differentiation 47/signal regulatory protein alpha (CD47/SIRPɑ) axis may provide new opportunities for the clinical application of engineered macrophages. The CD47/SIRPɑ axis is a major known pathway, repressing phagocytosis and activation of macrophages. In this article, we summarize the currently available evidence regarding the CD47/SIRPɑ axis, and immunotherapies based on blockage. In addition, we propose cell therapy strategies based on macrophage engineering.
免疫疗法在癌症治疗方面取得了重大进展。巨噬细胞在免疫系统中起着关键作用，既是吞噬细胞（清除病原体和癌细胞），又是抗原呈递细胞（激活 T 细胞）。然而，肿瘤免疫疗法的研究主要集中在适应性免疫系统。先天免疫细胞（如巨噬细胞）在癌症治疗中的作用尚未得到广泛研究。合成生物学的最新进展和对分化簇 47/信号调节蛋白α（CD47/SIRPɑ）轴的深入了解，可能为工程化巨噬细胞的临床应用提供新的机会。CD47/SIRPɑ 轴是一个主要的已知途径，抑制巨噬细胞的吞噬作用和激活。本文总结了目前关于 CD47/SIRPɑ 轴以及基于阻断的免疫疗法的相关证据。此外，我们还提出了基于巨噬细胞工程的细胞治疗策略。
